Patents by Inventor Suzanne Walker
Suzanne Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210346367Abstract: Provided herein are O-GlcNAc transferase (OGT) inhibitor compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., diabetes and complications thereof, neurodegenerative diseases, proliferative diseases such as cancers, autoimmune diseases, and inflammatory diseases) in a subject. Provided are methods of inhibiting OGT in a subject or biological sample.Type: ApplicationFiled: August 29, 2019Publication date: November 11, 2021Applicants: President and Fellows of Harvard College, The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Suzanne Walker Kahne, Sara Evelyn Schwanger Martin, Craig Joseph Thomas, Damien Yves Duveau
-
Patent number: 10106833Abstract: The present invention provides moenomycin-based probe compounds of Formula (I) for use in screening inhibitors of bacterial glycosyltransferases. The present invention also provides bacterial glycosyltransferase screening assays using compounds of Formula (I).Type: GrantFiled: March 13, 2013Date of Patent: October 23, 2018Assignee: President and Fellows of Harvard CollegeInventors: Daniel Evan Kahne, Suzanne Walker Kahne, Christian M. Gampe, Hirokazu Tsukamoto
-
Publication number: 20180162862Abstract: Described herein are compounds of Formula (I?), Formula (IA), Formulae (I)-(VII), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The invention also provides pharmaceutical compositions of the compounds for human and veterinary use. Compounds of the present invention are useful for inhibiting bacterial growth and therefore are useful in treating and/or preventing bacterial infections. Methods of using the compounds for treating and/or preventing a bacterial infection in a subject are also described.Type: ApplicationFiled: May 27, 2016Publication date: June 14, 2018Applicants: President and Fellows of Harvard College, Evotec International GmbHInventors: Christian M. Gampe, Daniel Evan Kahne, Suzanne Walker Kahne, Yuan Qia Cambridge, Stephen East, Alastair L. Parkes, Michelle South, James Hunter, Mark Whittaker, Martin Arthuis
-
Patent number: 9902985Abstract: The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I).Type: GrantFiled: April 5, 2013Date of Patent: February 27, 2018Assignee: President and Fellows of Harvard CollegeInventors: Daniel Evan Kahne, Suzanne Walker Kahne, Emma Doud, Christian M. Gampe, Hirokazu Tsukamoto
-
Publication number: 20170166558Abstract: The present invention provides inhibitors of O-GlcNAc transferase. Typically, the inhibitors are quinolinone-6-sulfonamides. The invention also provides pharmaceutical compositions thereof and methods for using the same in diabetes and complications thereof, metabolic diseases, neurodegenerative diseases, proliferative diseases (e.g., cancers), autoimmune diseases, and inflammatory diseases.Type: ApplicationFiled: July 1, 2015Publication date: June 15, 2017Applicants: President and Fellows of Harvard College, The UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and HumanInventors: Suzanne Walker Kahne, Rodrigo Fermin Ortiz Meoz, Craig Joseph Thomas, Damien Yves Duveau
-
Publication number: 20170081690Abstract: The methods and compositions described herein relate to the identification, isolation, and characterization of genes which encode proteins useful for the biosynthesis of transglycosylase inhibitors such as moes. The methods and compositions also relate to the production of such proteins, and their use in the synthesis of moes, the expression of moes, and the production of modified moes.Type: ApplicationFiled: August 24, 2015Publication date: March 23, 2017Applicant: President and Fellows of Harvard CollegeInventors: Suzanne Walker Kahne, Bohdan Omelyanovich Ostash
-
Patent number: 9573911Abstract: The present invention provides compounds of Formulae (I)-(V), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. In one aspect, compounds of the present invention are useful as glycosyltransferase inhibitors, in particular, O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) inhibitors. In another aspect, compounds of the present invention are useful as kinase inhibitors, in particular, PLK1 inhibitors, GSK3P inhibitors, or MAPKAPK2 inhibitors. The present invention further provides methods of using the inventive compounds, e.g., as biological probes to study the inhibition of OGT and/or kinase activity and as therapeutics, e.g., for the treatment of OGT-associated and/or kinase-associated conditions.Type: GrantFiled: July 6, 2012Date of Patent: February 21, 2017Assignee: President and Fellows of Harvard CollegeInventors: Suzanne Walker Kahne, Jiaoyang Jiang, Michael Block Lazarus
-
Publication number: 20160280732Abstract: The present invention provides compounds of Formula (I): or a pharmaceutically acceptable form thereof; wherein R1, R2, R3, R 6, R7, R12, RXX, Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): wherein X1, X2, X3, X4, X5, X6, X7, Y, Rc, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.Type: ApplicationFiled: February 29, 2016Publication date: September 29, 2016Applicant: President and Fellows of Harvard CollegeInventors: Daniel Evan Kahne, Suzanne Walker Kahne, Hirokazu Tsukamoto
-
Patent number: 9273084Abstract: The present invention provides compounds of Formula (I); or a pharmaceutically acceptable form thereof; wherein R1,R2,R3,R6,R7,R12,Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): Formula (II), wherein X1; X2, X3, X4, X5, X6, X7, Y, RC, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.Type: GrantFiled: April 5, 2013Date of Patent: March 1, 2016Assignee: President and Fellows of Harvard CollegeInventors: Daniel Evan Kahne, Suzanne Walker Kahne, Hirokazu Tsukamoto
-
Patent number: 9115358Abstract: The methods and compositions described herein relate to the identification, isolation, and characterization of genes which encode proteins useful for the biosynthesis of transglycosylase inhibitors such as moes. The methods and compositions also relate to the production of such proteins, and their use in the synthesis of moes, the expression of moes, and the production of modified moes.Type: GrantFiled: August 13, 2007Date of Patent: August 25, 2015Assignee: President and Fellows of Harvard CollegeInventors: Suzanne Walker, Bohdan Omelyanovich Ostash
-
Publication number: 20150166594Abstract: The present invention provides novel moenomycin analogs as well as pharmaceutical compositions thereof, methods of synthesis, and methods of use in treating an infection by administering an inventive compound to a subject in need thereof. The moenomycin analogs may be prepared synthetically, biosynthetically, or semi-synthetically. The analogs are particularly useful in treating or preventing infections caused by Gram-positive organisms. Certain inventive compounds may have a broader spectrum of coverage, which includes Gram-negative organisms.Type: ApplicationFiled: December 9, 2013Publication date: June 18, 2015Applicant: President and Fellows of Harvard CollegeInventors: Daniel Evan Kahne, Suzanne Walker Kahne, Masaatsu Adachi, Emma Doud, Shinichiro Fuse, Xiaonan Lin, Yi Zhang, Hirokazu Tsukamoto, Bohdan Omelyanovich Ostash
-
Publication number: 20150119354Abstract: The present invention provides compounds of Formula (I); or a pharmaceutically acceptable form thereof; wherein R1,R2,R3,R6,R7,R12,Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): Formula (II), wherein X1; X2, X3, X4, X5, X6, X7, Y, RC, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.Type: ApplicationFiled: April 5, 2013Publication date: April 30, 2015Inventors: Daniel Evan Kahne, Suzanne Walker Kahne, Hirokazu Tsukamoto
-
Publication number: 20150119561Abstract: The present invention provides methods of synthesizing moenomycin analogs of Formula (I). The present invention also provides compositions comprising a compound of Formula (I) and kits for synthesizing compounds of Formula (I).Type: ApplicationFiled: April 5, 2013Publication date: April 30, 2015Inventors: Daniel Evan Kahne, Suzanne Walker Kahne, Emma Doud, Christian M. Gampe, Hirokazu Tsukamoto
-
Patent number: 8993718Abstract: The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for identifying therapeutic compounds to treat glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention is also useful for identifying therapeutic compounds to treat de-glycosylation-associated disorders such as ischemic damage and traumatic injury. The invention also relates in part to assays that are useful for identifying and testing candidate compounds for modulating glycosylation of proteins and also relates in part to compounds to treat glycosylation-associated diseases and disorders.Type: GrantFiled: August 29, 2013Date of Patent: March 31, 2015Assignee: President and Fellows of Harvard CollegeInventors: Benjamin J. Gross, Suzanne Walker Kahne, Jonathan G. Swoboda
-
Publication number: 20150079618Abstract: The present invention provides moenomycin-based probe compounds of Formula (I) for use in screening inhibitors of bacterial glycosyltransferases. The present invention also provides bacterial glycosyltransferase screening assays using compounds of Formula (I).Type: ApplicationFiled: March 13, 2013Publication date: March 19, 2015Applicant: President and Fellows of Harvard CollegeInventors: Daniel Evan Kahne, Suzanne Walker Kahne, Christian M. Gampe, Hirokazu Tsukamoto
-
Patent number: 8957075Abstract: The present invention provides inhibitors of O-GIcNAc transferase. Typically, the inhibitors are quinolinone-6-sulfonamides. The invention also provides pharmaceutical compositions thereof and methods for using the same in diabetes and complications thereof, neurodegenerative diseases, cancers, autoimmune diseases, and inflammatory diseases.Type: GrantFiled: June 1, 2010Date of Patent: February 17, 2015Assignee: President and Fellows of Harvard CollegeInventors: Suzanne Walker Kahne, Michael Block Lazarus, Benjamin J. Gross
-
Publication number: 20140187444Abstract: The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for identifying therapeutic compounds to treat glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention is also useful for identifying therapeutic compounds to treat de-glycosylation-associated disorders such as ischemic damage and traumatic injury. The invention also relates in part to assays that are useful for identifying and testing candidate compounds for modulating glycosylation of proteins and also relates in part to compounds to treat glycosylation-associated diseases and disorders.Type: ApplicationFiled: August 29, 2013Publication date: July 3, 2014Applicant: President and Fellows of Harvard CollegeInventors: Benjamin J. Gross, Suzanne Walker Kahne, Jonathan G. Swoboda
-
Publication number: 20140163079Abstract: The present invention provides compounds of Formulae (I)-(V), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. In one aspect, compounds of the present invention are useful as glycosyltransferase inhibitors, in particular, O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) inhibitors. In another aspect, compounds of the present invention are useful as kinase inhibitors, in particular, PLK1 inhibitors, GSK3P inhibitors, or MAPKAPK2 inhibitors. The present invention further provides methods of using the inventive compounds, e.g., as biological probes to study the inhibition of OGT and/or kinase activity and as therapeutics, e.g., for the treatment of OGT-associated and/or kinase-associated conditions.Type: ApplicationFiled: July 6, 2012Publication date: June 12, 2014Applicant: President and Fellows of Harvard CollegeInventors: Suzanne Walker Kahne, Jiaoyang Jiang, Michael Block Lazarus
-
Patent number: 8604004Abstract: The present invention provides novel moenomycin analogs as well as pharmaceutical compositions thereof, methods of synthesis, and methods of use in treating an infection by administering an inventive compound to a subject in need thereof. The moenomycin analogs may be prepared synthetically, biosynthetically, or semi-synthetically. The analogs are particularly useful in treating or preventing infections caused by Gram-positive organisms. Certain inventive compounds may have a broader spectrum of coverage, which includes Gram-negative organisms.Type: GrantFiled: October 3, 2008Date of Patent: December 10, 2013Assignee: President and Fellows of Harvard CollegeInventors: Daniel Kahne, Suzanne Walker Kahne, Masaatsu Adachi, Emma Doud, Shinichiro Fuse, Xiaonan Lin, Yi Zhang, Hirokazu Tsukamoto, Bohdan Ostash
-
Patent number: 8598342Abstract: The present invention provides Wall Teichoic Acid biosynthesis inhibitors such as compound 1835F03 (targocil) and related synthetic analogs. The invention also provides pharmaceutical compositions thereof and methods for treating bacterial infection and the suppression of growth of bacterial cells by administering a Wall Teichoic Acid biosynthesis inhibitor. The invention is particularly useful for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA). The invention further provides procedures for the syntheses of Wall Teichoic Acid biosynthesis inhibitors. The invention also provides methods for the identification of antibacterial therapeutic agents.Type: GrantFiled: June 5, 2009Date of Patent: December 3, 2013Assignee: President and Fellows of Harvard CollegeInventors: Suzanne Walker Kahne, Jonathan G. Swoboda, Timothy C. Meredith, Kyungae Lee, Jennifer Campbell